ArticleBMC microbiology2026
Cefiderocol resistance in a clinical ST11-KL64 hypervirulent Klebsiella pneumoniae isolate mediated by a novel CirA truncation and SHV-12 β-lactamase.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) infections have emerged as a major global public health threat. Cefiderocol is a novel siderophore-conjugated cephalosporin with potent activity to treat severe infections caused by CRKP. In this study, we investigated the underlying mechanisms leading to cefiderocol resistance in an ST11-KL64 hypervirulent K. pneumoniae FK3023 isolated from a patient with infective fever and chronic kidney disease in China.
methodsWhole genome sequencing (WGS), amino acid sequences alignment, cirA gene complementation and lactamases genes cloning assays were performed to elucidate the molecular basis of cefiderocol resistance. Pathogenicity was evaluated by quantitative siderophore production, string test, capsule quantification, and a Galleria mellonella infection model.
resultsThis strain carried a hybrid plasmid that contained both virulence and resistance determinants, including key virulence factors (iutA-iucABCD operon and rmpA gene) and β-lactamases genes (blaKPC−2, blaTEM−1B, blaCTX−M−3, blaCTX−M−65). Compared to the wild-type siderophore receptor CirA, K. pneumoniae FK3023 carried 119 nucleotide deletion (c.1830_1948del), leading to a frameshift, followed by a premature stop codon (Val611TyrfsTer32), resulting in a novel mutation in CirA. K. pneumoniae FK3023 complemented with the wild-type cirA showed a substantial decrease in cefiderocol MIC, further confirming the function of CirA. Each of the six identified β-lactamases genes in K. pneumoniae FK3023 was cloned into a pUC vector, and then expressed in Escherichia coli cells. The E. coli strains carrying blaSHV−12 showed an increase in cefiderocol MIC compared to the E. coli strains carrying empty vectors.
conclusionsIn conclusion, we described a clinical ST11-KL64 hypervirulent K. pneumoniae isolate exhibiting cefiderocol resistance likely mediated by a novel CirA truncation and blaSHV−12. K. pneumoniae FK3023 also carried the hybrid plasmid and two additional resistance plasmids, highlighting the convergence of hypervirulence and multidrug resistance and underscoring the challenges for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.